Clinical Trial Update: Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immunogenicity and safety of a meningococcal serogroup B vaccine given in a 3-dose schedule to healthy adolescents aged 12-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal serogroup B vaccine (Meningococcal serogroup B vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED